Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

LENZ Therapeutics Q1 2024 GAAP EPS $(3.53) Misses $(0.90) Estimate

Author: Benzinga Newsdesk | May 08, 2024 04:31pm
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(3.53) per share which missed the analyst consensus estimate of $(0.90) by 292.22 percent. This is a 45.69 percent increase over losses of $(6.50) per share from the same period last year.

Posted In: LENZ